Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92 Data from the ...
Investor's Business Daily on MSN
Spyre Therapeutics flies on Takeda-rivaling ulcerative colitis results
Spyre Therapeutics stock soared to a four-year high Monday on positive 12-week test results for its ulcerative colitis ...
For patients who experience endoscopic remission of ulcerative colitis (UC), signs of active disease on histology did not affect their risk of clinical relapse, according to a large prospective study ...
In patients with ulcerative colitis who had endoscopic healing, achieving transmural healing was associated with longer relapse-free survival. Women and those who had received multiple advanced ...
InvestorsHub on MSN
Spyre Therapeutics shares jump after positive ulcerative colitis trial data
Spyre Therapeutics (NASDAQ:SYRE) shares climbed 25% on Monday after the company reported that its investigational therapy ...
Intestinal ultrasound (IUS) is non-invasive, cost-effective, and accurate to determine disease activity in ulcerative colitis (UC). In this study, we prospectively evaluated IUS for treatment response ...
The diagnosis of ulcerative colitis (UC) is based on clinical evaluation and medical history and confirmed through laboratory, radiologic, endoscopic and histologic findings. Before making the ...
STOCKHOLM, Feb. 21, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new long-term data from the QUASAR long-term extension (LTE) study showing that TREMFYA® (guselkumab) sustained ...
Takeda presented promising data on its ulcerative colitis and Crohn’s disease drug Entyvio at the World Congress of Gastroenterology at ACG2017, Oct. 13 to Oct. 18 in Orlando, Fla. The data suggests ...
The American Gastroenterological Association has updated guidance for the treatment of ulcerative colitis to recommend using higher efficacy drugs in earlier stages of treatment, Medscape Medical News ...
More than 80% of those treated with TREMFYA ® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension study, showing lasting disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results